Cerus (NASDAQ: CERS) and Delcath Systems (OTCMKTS:DCTHD) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, profitability, risk, institutional ownership, analyst recommendations, earnings and dividends.
Earnings and Valuation
This table compares Cerus and Delcath Systems’ revenue, earnings per share and valuation.
||Earnings Per Share
Delcath Systems has lower revenue, but higher earnings than Cerus.
Risk and Volatility
Cerus has a beta of 1.81, suggesting that its share price is 81% more volatile than the S&P 500. Comparatively, Delcath Systems has a beta of -0.61, suggesting that its share price is 161% less volatile than the S&P 500.
This is a summary of current ratings and price targets for Cerus and Delcath Systems, as provided by MarketBeat.com.
||Strong Buy Ratings
Cerus presently has a consensus price target of $5.33, indicating a potential downside of 20.04%. Given Cerus’ higher probable upside, research analysts plainly believe Cerus is more favorable than Delcath Systems.
Institutional & Insider Ownership
60.1% of Cerus shares are held by institutional investors. 6.8% of Cerus shares are held by company insiders. Comparatively, 0.0% of Delcath Systems shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
This table compares Cerus and Delcath Systems’ net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
Cerus beats Delcath Systems on 9 of the 11 factors compared between the two stocks.
Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System is based on its proprietary technology for controlling biological replication; and targets and inactivates blood-borne pathogens, such as viruses, bacteria, and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, and red blood cell transfusion products. The company's INTERCEPT Blood Systems for platelets and plasma are designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; and INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion. It markets platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was founded in 1991 and is headquartered in Concord, California.
About Delcath Systems
Delcath Systems, Inc. is a late-stage clinical development company with early commercial activity in Europe focused on cancers of the liver. The Company is a specialty pharmaceutical and medical device company developing its product, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS). The Company’s system delivers and filters melphalan hydrochloride, which is marketed as a device under the trade name Delcath Hepatic CHEMOSAT Delivery System for Melphalan (CHEMOSAT). The Company’s focus is on the execution of the clinical development program (CDP) in ocular melanoma liver metastases (mOM), intrahepatic cholangiocarncinoma (ICC), hepatocellular carcinoma (HCC or primary liver) and other cancers that are metastatic to the liver.
Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.